Literature DB >> 23211493

The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia.

N Y Lee1, M S Roh, S H Kim, D C Jung, H Y Yu, K H Sung, I W Chung, T Youn, U G Kang, Y M Ahn, Y S Kim.   

Abstract

Widely ranging prevalence rates for metabolic syndrome (MetS) in patients taking clozapine have been reported on the basis of various criteria, and most studies have been carried out in non-Asian countries. Therefore, we examined the prevalence of MetS in Korean patients using three commonly applied criteria with two waist-circumference cutoff values. The indirectly standardized prevalence ratio (ISPR) was estimated using data from the Fourth Korean National Health and Nutrition Examination Survey (KNHNES, 2007) to compare the prevalence of MetS in patients with that in the general population. In addition, we also examined whether serum alanine aminotransferase (ALT) and aspartate aminotransferase levels serve as biochemical markers for the identification of MetS. We reviewed the electromedical records of patients with schizophrenia who had taken clozapine as the sole antipsychotic for 3 months or more. The prevalence of MetS ranged from 34.5 to 46.9%, and the ISPR ranged from 2.4 to 2.8, given the three definitions of MetS and the two waist-circumference cutoff points for women. The ISPR for MetS among those aged 18-30 years was the highest and decreased with age in both men and women. After adjusting for age, patients with normal serum ALT levels who were in the top third were significantly more likely to have MetS compared with those who were in the bottom third. Logistic regression analysis showed that serum ALT levels and use of antidepressants were significantly related to the presence of MetS. Korean patients with schizophrenia who were receiving clozapine as the sole antipsychotic showed a high prevalence of MetS. Although we found substantial differences in the prevalence according to criteria, the ISPR indicated significantly higher rates of MetS in this group than in the general population. In the general population, younger patients had a much higher risk for MetS than older patients. Elevated levels of serum ALT that were in the normal range were associated with the presence of MetS, which suggests the possibility of using serum ALT level as an early indicator for MetS in patients treated with clozapine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23211493     DOI: 10.1097/YIC.0b013e32835b99bd

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  5 in total

1.  Aminotransferase levels as a prospective predictor for the development of metabolic syndrome in patients with schizophrenia.

Authors:  Eun Young Kim; Se Hyun Kim; Nam Young Lee; Jin Sang Yoon; Chul Eung Kim; Yong Sik Kim; Yong Min Ahn
Journal:  Psychopharmacology (Berl)       Date:  2014-05-13       Impact factor: 4.530

2.  Impact of Lurasidone on Metabolic Parameters and Prolactin Levels Based on Differences of Psychiatric Diagnosis, Dosage, and Introducing Methods: An Observational Study.

Authors:  Masaru Nakamura; Takahiko Nagamine
Journal:  Innov Clin Neurosci       Date:  2022 Apr-Jun

3.  Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics.

Authors:  Seong Hoon Jeong; Nam Young Lee; Se Hyun Kim; In Won Chung; Tak Youn; Ung Gu Kang; Yong Min Ahn; Han Young You; Yong Sik Kim
Journal:  Psychiatry Investig       Date:  2018-06-21       Impact factor: 2.505

4.  Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review.

Authors:  Marius H Sneller; Nini de Boer; Sophie Everaars; Max Schuurmans; Sinan Guloksuz; Wiepke Cahn; Jurjen J Luykx
Journal:  Front Psychiatry       Date:  2021-03-29       Impact factor: 4.157

Review 5.  Metabolic syndrome in schizophrenia.

Authors:  Nidhi Malhotra; Sandeep Grover; Subho Chakrabarti; Parmanand Kulhara
Journal:  Indian J Psychol Med       Date:  2013-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.